<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="45301">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02003326</url>
  </required_header>
  <id_info>
    <org_study_id>13AOI07</org_study_id>
    <nct_id>NCT02003326</nct_id>
  </id_info>
  <brief_title>Strain and Blood Inflammatory Markers as Prognostic Tools for ARDS AMIS (ARDS - Markers of Inflammation - Strain)</brief_title>
  <acronym>AMIS</acronym>
  <official_title>Strain and Blood Inflammatory Markers as Prognostic Tools for ARDS AMIS (ARDS - Markers of Inflammation - Strain)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>France: Committee for the Protection of Personnes</authority>
    <authority>France: The Commission nationale de l’informatique et des libertés</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective is determine the strain measured at the bedside could be a dynamic prognostic
      marker of during Acute respiratory Distress Syndrome (ARDS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Nowadays ARDS severity, and therapeutic efficiency are evaluated using PaO2/FiO2 ratio.
      Inflammation is a cornerstone of ARDS and the ratio is not a sufficiently accurate tool to
      predict the evolution of ARDS. A reproducible marker would be helpful to adapt the
      therapeutics and maybe limit their deleterious effects.

      The investigators made the hypothesis that patients moderate to severe ARDS (comparable
      PaO2/FiO2 ratio) with a higher strain may have higher inflammation.

      Moderate/severe ARDS will be ventilate with protective ventilation (low tidal volume and
      PEEP set to limit plateau pressure under 30cmH2O). Markers of inflammation will be measured
      in the broncho Alveolar Lavage the first day and in the blood the following days. Strain
      will be measured at the bedside using the nitrogen washout-washin. Markers of inflammation
      and strain will be analysed with ventilatory and oxygenation.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">October 2014</completion_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Intervention Model: Single Group Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>measure of the number of hours spent with a PaO2/FiO2 ratio under 200mmHg</measure>
    <time_frame>until the 13th day</time_frame>
    <safety_issue>No</safety_issue>
    <description>measure of the number of hours spent with a PaO2/FiO2 ratio under 200mmHg : day 0,1,2,4,6,13</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality at D28</measure>
    <time_frame>at the 28th day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Verify if the patient is death at the 28th day</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ventilatory free days at D28</measure>
    <time_frame>at the 28th day</time_frame>
    <safety_issue>No</safety_issue>
    <description>To determine if the patient is free ventilatory at the 28th day</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Acute Respiratory Distress Syndrome.</condition>
  <arm_group>
    <arm_group_label>Inflammatory markers</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients with inclusion criteria (ARDS moderate and severe: Berlin definition) and absence of non inclusion criteria will have a broncho alveolar wash at day 0 and blood sample every three day to measure inflammatory markers. All patients will receive protective ventilation with low tidal volume and pressures limited (Pplat &lt;30cmH2O). End-Expiratory Lung Volume and strain will be measured every 6 hours from the inclusion to the extubation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Inflammatory markers</intervention_name>
    <arm_group_label>Inflammatory markers</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe ARDS (Berlin Definition)

          -  Acute beginning &lt;1 week

          -  PaO2/FiO2 ratio ≤ 200 after 24h mechanical ventilation with PEEP≥5cmH2O

          -  Bilateral opacities on chest X-ray

          -  Respiratory failure not fully explain by cardiac failure or fluid overload

          -  Informed consent signed by the next of kin and secondarily by the patient when awake

          -  Patient with social insurance

        No Inclusion criteria

          -  Age &lt; 18

          -  Pregnancy a pregnancy test will be done to women of childbearing age

          -  Chronic obstructive pulmonary disease

          -  Severe hypoxemia PaO2/FiO2 &lt;50% with high PEEP

          -  Immunosuppressive treatment

          -  Immunodeficiency onco-hematology, HIV
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean DELLAMONICA, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Nice Hôpital de l'Archet</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean DELLAMONICA, MD</last_name>
    <phone>+33 4 92 03 55 10</phone>
    <email>dellamonica.j@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elodie FERRET, MD</last_name>
    <phone>+33 4 92 03 55 10</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Réanimation Médicale CHU de Nice - Hôpital de l'Archet</name>
      <address>
        <city>Nice</city>
        <zip>06003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean DELLAMONICA, MD</last_name>
      <phone>+33 4 92 03 55 10</phone>
      <email>dellamonica.j@chu-nice.fr</email>
    </contact>
    <contact_backup>
      <last_name>Elodie FERRET, MD</last_name>
      <phone>+33 4 92 03 55 10</phone>
    </contact_backup>
    <investigator>
      <last_name>Jean DELLAMONICA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 2, 2013</lastchanged_date>
  <firstreceived_date>November 7, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Inflammation</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
